BDTX vs. SPPI, CCCC, CGEN, ALEC, ITOS, IMTX, INBX, RLAY, MESO, and HUMA
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Spectrum Pharmaceuticals (SPPI), C4 Therapeutics (CCCC), Compugen (CGEN), Alector (ALEC), iTeos Therapeutics (ITOS), Immatics (IMTX), Inhibrx (INBX), Relay Therapeutics (RLAY), Mesoblast (MESO), and Humacyte (HUMA). These companies are all part of the "medical" sector.
Black Diamond Therapeutics (NASDAQ:BDTX) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.
Spectrum Pharmaceuticals received 447 more outperform votes than Black Diamond Therapeutics when rated by MarketBeat users. However, 64.52% of users gave Black Diamond Therapeutics an outperform vote while only 63.91% of users gave Spectrum Pharmaceuticals an outperform vote.
In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Spectrum Pharmaceuticals. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 0 mentions for Spectrum Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 0.72 beat Spectrum Pharmaceuticals' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.
Black Diamond Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 131.21%. Given Black Diamond Therapeutics' higher probable upside, equities analysts plainly believe Black Diamond Therapeutics is more favorable than Spectrum Pharmaceuticals.
Black Diamond Therapeutics has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500.
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 21.7% of Spectrum Pharmaceuticals shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 2.7% of Spectrum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Black Diamond Therapeutics' return on equity of -72.94% beat Spectrum Pharmaceuticals' return on equity.
Spectrum Pharmaceuticals has higher revenue and earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Spectrum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Black Diamond Therapeutics beats Spectrum Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
